Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

ABSTRACT:

Purpose

The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.

Experimental design

We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan-Meier method.

Results

A total of 4,736 patients were included, of whom 1,487 received ASIs and 783 received other antihypertensive agents. Overall, ASI users demonstrated improved overall survival (OS) compared with users of other antihypertensive agents (adjusted HR, 0.838, P = 0.0105, 26.68 v

SUBMITTER: McKay RR 

PROVIDER: S-EPMC4566854 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature